dr. M. (Hilde) Jalving

No picture available
E-mail:
m.jalving umcg.nl

Research

  1. 2020
  2. DOCC Investigators, de Joode, K., Tol, J., Westgeest, H. M., Beerepoot, L. V., van den Berkmortel, F. W. P. J., Mutsaers, P. G. N. J., van Diemen, N. G. J., Visser, O. J., Oomen-de Hoop, E., Bloemendal, H. J., van Laarhoven, H. W. M., Hendriks, L. E. L., Haanen, J. B. A. G., de Vries, E. G. E., Dingemans, A. M. C., & van der Veldt, A. A. M. (2020). Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. European Journal of Cancer, 141, 171-184. https://doi.org/10.1016/j.ejca.2020.09.027
  3. Levy, S., Aarts, M. J. B., Eskens, F. A. L. M., Keymeulen, K. B. M. I., Been, L. B., Grunhagen, D., Van Akkooi, A., Jalving, M., & Tesselaar, M. E. T. (2020). Avelumab for advanced Merkel cell carcinoma in the Netherlands: A real-world cohort. Journal for immunotherapy of cancer, 8(2), [e001076]. https://doi.org/10.1136/jitc-2020-001076
  4. Carneiro, A., Amaral, T. M. S., Brandao, M., Scheffler, M., Bol, K., Ferrara, R., Jalving, M., Lo Russo, G., Marquez-Rodas, I., Matikas, A., Mezquita, L., Morgan, G., Onesti, C. E., Pilotto, S., Saloustros, E., & Trapani, D. (2020). Disparities in access to oncology clinical trials in Europe in the period 2009-2019. Annals of Oncology, 31, S1196-S1196. https://doi.org/10.1016/j.annonc.2020.08.2301
  5. Gelderblom, H., Gietema, J. A., Desar, I. M. E., Ajmone, N. M., Jalving, M., Kroep, J. R., Nicolas, V., Vaslin, A., Tobal, K., Purcea, D., van Haren, S. F., & Damstrup, L. (2020). First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours. Annals of Oncology, 31, S501-S502. https://doi.org/10.1016/j.annonc.2020.08.715
  6. Versluis, J. M., Hendriks, A. M., Weppler, A., Brown, L., de Joode, K., Suijkerbuijk, K. P. M., Zimmer, L., Kapiteijn, E., Allayous, C., Johnson, D. B., Hepner, A., Mangana, J., Bhave, P., Jansen, Y., Trojaniello, C., Atkinson, V., Storey, L., de Vries, E. G. E., Blank, C. U., & Jalving, M. (2020). The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition. Annals of Oncology, 31, S733-S734. https://doi.org/10.1016/j.annonc.2020.08.1204
  7. Diéras, V., Han, H. S., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J-P., Puhalla, S. L., Bondarenko, I., Campone, M., Jakobsen, E. H., Jalving, M., Oprean, C., Palácová, M., Park, Y. H., Shparyk, Y., Yañez, E., Khandelwal, N., Kundu, M. G., Dudley, M., ... Arun, B. K. (2020). Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, 21(10), 1269-1282. https://doi.org/10.1016/S1470-2045(20)30447-2
  8. Levy, S., Aarts, M. J. B., Eskens, F., Keymeulen, K. B. M., Been, L. B., GrUnhagen, D. J., van Akkooi, A. C. J., Jalving, M., & Tesselaar, M. (2020). Avelumab for Advanced Merkel Cell Carcinoma in the Netherlands; A Nationwide Survey. Neuroendocrinology, 110, 232-232.
  9. 2019
  10. Eggen, A., Richard, N., Shen, G., Shultz, D., Leighl, N., Liu, G., Sun, A., Bosma, I., Reyners, A., Jalving, M., Rodin, G., & Edelstein, K. (2019). Cognitive concerns and performance in patients with metastatic non-small cell lung cancer (mnsclc). Neuro-Oncology, 21, 159.
  11. Levy, S., Aarts, M. J. B., Eskens, F. A., Keymeulen, K., Been, L., Grunhagen, D. J., van Akkooi, A. C. J., Jalving, M., & Tesselaar, M. E. T. (2019). Avelumab for advanced Merkel cell carcinoma in the Netherlands: A nationwide survey. Annals of Oncology, 30, 537-538.
  12. Dieras, V. C., Han, H. S., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J-P., Puhalla, S. L., Bondarenko, I., Campone, M., Jakobsen, E. H., Jalving, M., Oprean, C., Palacova, M., Park, Y. H., Shparyk, Y., Yanez, E., Dudley, M., Ratajczak, C. K., Maag, D., & Arun, B. K. (2019). Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer. Annals of Oncology, 30, 857-858.
  13. Mourits, M. J. E., Eggink, F., Jalving, M., de Bruyn, M., Bart, J., & Nijman, H. (2019). Ovarian cancer. In Textbook of Obstetrics and Gynaecology: a life course approach Bohn, Stafleu, Van Loghum. https://www.bsl.nl/shop/textbook-of-obstetrics-and-gynaecology-9789036821308.html
  14. 2018
  15. Jalving, M., & de Vries, E. G. E. (2018). Immune Checkpoint Blockade: Response Patterns and Assessment of Response. In J. B. A. G. Haanen , R. Califano, I. Lugowska, & M. C. Garassino (Eds.), ESMO Handbook of Immuno-Oncology (1 ed., pp. 258-266). (ESMO Handbook Series). the European Society for Medical Oncology (ESMO). https://oncologypro.esmo.org/Education-Library/Handbooks/Immuno-Oncology
  16. 2017
  17. 2016
  18. Munasinghe, W., Stodtmann, S., Tolcher, A., Calvo, E., Gordon, M., Jalving, M., de Vos-Geelen, J., Medina, D., Bergau, D., Nuthalapati, S., Hoffman, D., Shepherd, S., & Xiong, H. (2016). Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study. Cancer Chemotherapy and Pharmacology, 78(5), 1003-1011. https://doi.org/10.1007/s00280-016-3156-x
  19. 2015
  20. 2014
Previous 1 2 Next

ID: 223669